Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PRAX
PRAXIS PRECISION MEDICINES, INC.
NASDAQ
$375.94
▲ UP 3.12% (11.36)

KEY STATISTICS

Market Cap$10.48 B
52w High$392.70
52w Low$37.19
Dividend Yield—
Frequency—
P/E-29.08
Volume413.32K
Shares Out.27.88M

COMPANY

LEADERSHIP

Marcio Silva De'Souza
CHIEF EXECUTIVE
Marcio Silva De'Souza

COMPENSATION 2026

Salary$659,200
Stock Awards$2,368,125
Incentive Plan Pay$1,483,200
All Other Comp.$506,998
Total$8,708,648

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 16, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
168

PRICE TARGET

Target High$1201.00
Target Low$162.00
Target Median$575.00
Target Consensus$603.83

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$130.77K
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2023-11-29Reverse1:15

PRICE

$375.94 ▲ UP 3.12% (+$11.36)
OVERLAYS
$368$375$3839:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM375.94

About Praxis Precision Medicines, Inc.

https://www.praxismedicines.com ↗

Praxis Precision Medicines, a Boston-based clinical-stage biopharma, develops CNS disorder therapies like PRAX-114 and PRAX-944, targeting depression, tremor, epilepsy, and related conditions through innovative drug candidates and collaborations.

INDUSTRY

Biotechnology

A PRODUCT PRAXIS PRECISION MEDICINES, INC. IS KNOWN FOR

Ulixacaltamide
Ulixacaltamide

Ulixacaltamide is an investigational oral drug for essential tremor, showing positive Phase 3 results, FDA Breakthrough Therapy Designation, and a submitted NDA as Praxis' most advanced pipeline candidate.

COMPETITORS

COMPETITOR
AXSM COMPARE
NBIX COMPARE
RAPP COMPARE
XENE COMPARE

Revenue by Products

IconPRODUCTQ4-2023Q1-2024Q2-2024Q4-2024
Option Exercise Fee— — — $6M
License$400K $400K $400K —

ETFS HOLDING THIS STOCK

ETFS HOLDING
173
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.01% · 888.2K
IWM
0.29% · 643.7K
XBI
1.39% · 431.9K
SCHA
0.20% · 124.5K
FESM
0.33% · 57.8K
TMSL
0.28% · 23.3K
XRS2.F
0.29% · 22.0K
LABU
0.97% · 17.2K
DFAS
0.03% · 13.0K
RSSL
0.29% · 12.0K
USVM
0.16% · 7.8K
JHMM
0.04% · 7.7K
JSML
0.70% · 7.4K
PRFZ
0.09% · 7.4K
GSC
0.92% · 7.3K
BBSC
0.31% · 6.2K
BKMC
0.24% · 4.2K
LFSC
1.01% · 3.5K
IQSM
0.34% · 3.2K
FNY
0.17% · 2.7K
AVUS
0.00% · 1.6K
MEDI
1.01% · 1.2K
BBC
0.83% · 1.2K
HELX
1.31% · 1.1K
TILT
0.02% · 1.1K
MNTL
0.55% · 1.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
81.78%
HOLDERS
373
TOP 12 OF 373 · RANKED BY POSITION SIZE
Janus Henderson Group Plc
3.2M sh · $954.83M
Orbis Allan Gray Ltd
2.5M sh · $796.61M
Adage Capital Partners Gp, L.L.C.
2.4M sh · $125.83M
Blackrock, Inc.
2.3M sh · $749.07M
Fmr LLC
2.3M sh · $775.68M
Perceptive Advisors LLC
2.0M sh · $681.63M
Baker Bros. Advisors LP
1.8M sh · $586.95M
Point72 Asset Management, L.P.
1.5M sh · $79.29M
Vanguard Group Inc
1.5M sh · $430.6M
Blackrock Inc.
1.3M sh · $53.52M
State Street Corp
1.0M sh · $343.66M
Price T Rowe Associates Inc /Md/
1.0M sh · $53.19M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Souza Marcio
Sale · 20.5K shares
2026-07-08
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Souza Marcio
Sale · 2.6K shares
2026-07-08
★
DIRECTOR
DeSimone Jill
Sale · 1.8K shares
2026-06-24
★
DIRECTOR
DeSimone Jill
Sale · 2.9K shares
2026-06-24

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 10
OUTPERFORM 3
EQUAL WEIGHT 1
UNDERPERFORM 1
OVERWEIGHT 1
16 GRADES IN THE LAST 12 MONTHS
Goldman Sachs BUY Wells Fargo EQUAL WEIGHT RBC Capital OUTPERFORM Needham BUY BTIG BUY HC Wainwright & Co. BUY Deutsche Bank BUY Baird OUTPERFORM

SECTORS PEERS

PEERPRICE
KYMR$119.80COMPARE
IMVT$44.37COMPARE
CRNX$84.69COMPARE
XENE$60.77COMPARE
LGND$286.29COMPARE
ACAD$29.50COMPARE
VKTX$33.89COMPARE